天坛生物：下属企业成都蓉生药业获得注射用重组人凝血因子Ⅷ＜12岁适应症人群临床试验总结报告

Core Viewpoint - TianTan Biological (600161.SH) announced that its subsidiary Chengdu Rongsheng Pharmaceutical has completed the clinical trial for the injectable recombinant human coagulation factor VIII for the population under 12 years old, achieving positive results in safety and efficacy [1] Group 1 - The clinical trial summary report indicates that the drug shows good safety for pediatric patients with Hemophilia A [1] - The treatment significantly reduces the frequency of bleeding episodes in children [1] - Improvements were observed in joint health scores (HJHS), number of target joints, and quality of life scores (CHO-KLAT) for the patients [1]